Home › Steatotic Liver Disease › Kansas
Steatotic Liver Disease clinical trials in Kansas
8 studies for Steatotic Liver Disease are looking for participants at sites in Kansas.
Cities in Kansas
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Topeka
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Nov 13, 2026 · NCT06613698A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Topeka
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Nov 12, 2026 · NCT06528314Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Kansas Medical Clinic, Topeka
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Nov 9, 2026 · NCT07631637A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Kansas City
- 89bio Clinical Study Site, Topeka
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Topeka
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 23, 2026 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- AMR Clinical, El Dorado
- Johnson County Clinical Trials, Lenexa
- Cotton O'Neil Digestive Health Center, Topeka
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07165028A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Topeka
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Topeka
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.